ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achieving complete tumor removal confirmed by pathology. The treatment showed a favorable safety profile across escalating doses. These findings suggest Padeliporfin VTP could expand surgical options for patients previously deemed inoperable, with the company planning further clinical development and regulatory discussions.
ImPact Biotech's early clinical results in pancreatic cancer provide context for the health sector's market activity on Pluang. As of Oct 23, 2026 18:41 WIB, out of 150 priced health-sector US stocks, 31 rose and 112 fell. Notable movers include NUWE at USD 0.53 with a 7.63% gain and 100% buy order activity, Moderna at USD 194.21 down 4.16%, and NUVB at USD 4.85 up 3.19%.
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...
S&P Global Ratings has upgraded EssilorLuxottica's long-term credit rating to A+ with a stable outlook, recognizing the company's strong organic growth, solid cash flow, and robust balance sheet. The rating agency highlighted EssilorLuxottica's strat...
